Quick Takeaways
- JOHNSON & JOHNSON filed SCHEDULE 13G/A for Rapport Therapeutics, Inc. Common Stock, $0.001 par value (RAPP).
- Disclosed ownership: 4.9%.
- Date of event: 30 Sep 2025.
JOHNSON & JOHNSON - 30 Sep 2025 SCHEDULE 13G/A Report for Rapport Therapeutics, Inc. Common Stock, $0.001 par value (RAPP)
- Filing Manager
- JOHNSON & JOHNSON
- Reporting Manager
- JOHNSON & JOHNSON
- Symbol
- RAPP
- Shares outstanding
- 36,418,714 shares
- Disclosed Ownership
- 1,784,517 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 22 Oct 2025, 17:09:06 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JOHNSON & JOHNSON disclosed 4.9% ownership in Rapport Therapeutics, Inc. Common Stock, $0.001 par value (RAPP) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 22 Oct 2025, 17:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | 4.9% | 1,784,517 | 0 | 1,784,517 | /s/ Marc Larkins | Mark Larkins/Secretary | |
| Johnson & Johnson Innovation - JJDC, Inc. | 4.9% | 1,784,517 | 0 | 1,784,517 | /s/ Jill McManus | Jill McManus/Assistant Treasurer |